Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy - Summary - MDSpire
To investigate the effect of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on lung cancer patients with hypertension undergoing immune checkpoint inhibitor (ICI) therapy, focusing on specific survival benefit metrics and cardiotoxicity reduction.
Key Findings:
39 patients received ARNIs, matched with 114 control patients not receiving ARNIs.
The overall population had a mean age of 67.94 years, predominantly male (88.2%), with most diagnosed with NSCLC (92.2%).
No significant differences in baseline characteristics or cardiac risk factors between ARNIs and control groups, but specific outcome data should be included.
Interpretation:
ARNIs may provide a potential benefit in managing hypertension and mitigating cardiotoxicity in lung cancer patients receiving ICIs, although the study's findings require further validation, including larger sample sizes and multi-center studies.
Limitations:
Single-center study may limit generalizability.
Retrospective design may introduce selection bias.
Small sample size may affect the robustness of findings.
Conclusion:
ARNIs could be a beneficial adjunct therapy for lung cancer patients with hypertension undergoing ICI treatment, warranting further investigation.
New multisociety guidance identifies menstrual irregularities as potential early markers of cardiovascular risk, extending prevention efforts into adolescence.
Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.
